Skip to main content
. Author manuscript; available in PMC: 2017 Dec 8.
Published in final edited form as: J Med Chem. 2016 Nov 16;59(23):10601–10618. doi: 10.1021/acs.jmedchem.6b01208

Figure 1. Discovery of compound 1, a G protein-biased D2R partial agonist.

Figure 1

Benzothiazole substitution and linker modification of a β-arrestin-biased D2R agonist led to compound 1, which is a D2R Gi/o partial agonist with weak efficacy for β-arrestin recruitment.